The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16). Read more
Castor establishes new US operations, building on leadership position across the EU Amsterdam, The Netherlands and Hoboken, New Jersey, USA, October 7, 2019: Castor, a health-tech company that helps medical researchers maximize the value of research data, today announces its international business expansion. By strengthening its presence in the US and the EU, Castor can […]
Novel deep-learning approach for predicting and explaining the key prognostic factors for patients with Mesothelioma Paris, France and New York, USA, October 7th, 2019 – Owkin, which is developing machine learning technologies to advance medical research, today announces publication of a paper in Nature Medicine that showcases its breakthrough analysis of tumour biology using interpretable […]
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company’s lead compound Nefecon, currently in Phase 3 clinical trials in IgA nephropathy (IgAN). In a written response received from EMA, the agency agreed that it could support CMA […]
Cambridge, UK and New York, US, 24 September 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States. Tania is based at Artios’s new offices […]
